AAN Vagus Nerve Stimulation For The Treatment Of Epilepsy Guideline Summary - Guideline Central

Document Overview

Document Title
Vagus Nerve Stimulation For The Treatment Of Epilepsy
Authoring Society

American Academy of Neurology

Document Publication Date
Aug 28, 2013
Page Last Reviewed/Updated
May 6, 2026
Document Type
Guideline
Country of Publication
United States
Full Text Freely Available
Yes
Full Text Guideline
n.neurology.org/content/81/16/1453.full
Source Citation

Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy Report of the Guideline Development Subcommittee of the American Academy of Neurology George L. Morris, David Gloss, Jeffrey Buchhalter, Kenneth J. Mack, Katherine Nickels, Cynthia Harden Neurology Oct 2013, 81 (16) 1453-1459; DOI: 10.1212/WNL.0b013e3182a393d1
 


Document Scope, Criteria, and Use Cases

Document Objectives
To evaluate the evidence since the 1999 assessment regarding efficacy and safety of vagus nerve stimulation (VNS) for epilepsy, currently approved as adjunctive therapy for partial-onset seizures in patients >12 years.
Scope
Assessment and Screening, Management, Treatment
Diseases/Conditions (MeSH)

D004827 - Epilepsy

D004827 - Epilepsy

Keywords
epilepsy, vagus nerve stimulation
Inclusion Criteria
Female, Male, Adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, Nurse Practitioner, Occupational Therapist, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resources
Methodology Supplement Evidence Tables
Number of Source Documents
40
Literature Search End Date
Wednesday, February 1, 2012
Includes peer/external review process?
Yes
Includes public comment process?
No
Methodologist involvement?
Yes
Patient involvement?
No
Includes multi-disciplinary group?
Yes
Includes systematic review?
Yes
Grades quality of strength of evidence?
Yes
Grades quality of strength of recommendation?
Yes
Discloses funding source?
Yes
Discloses conflicts of interest?
Yes
Includes benefits/harms analysis with recommendations?
No
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.